Insulet Corporation (PODD) has been consistently performing well in the market with noticeable developments. Multiple reputable wealth management firms have increased their stake in the company, reflecting optimism and confidence for its future progress. The launch of the revolutionary Omnipod® 5, gaining FDA approval for Type 2 Diabetes and expanding its availability across the globe have contributed significantly to the company's growth. Further fuelled by Q3 revenue that rose by 26% to $544 million and a victorious stand with a $452 million reward in a major trade secret case, investors have been eager to buy or hold PODD stocks. Therefore, the company's shares have reached a new 12-month high, adding more momentum to the stock for the long-term. However, it's also notable that there have been insider sell-offs, which could be due to personal reasons or dynamics of the stock's performance. Future projections remain bullish as Insulet continues to innovate and scale globally.
Insulet Corporation PODD News Analytics from Thu, 22 Feb 2024 08:00:00 GMT to Sat, 25 Jan 2025 14:00:30 GMT -
Rating 8
- Innovation 7
- Information 6
- Rumor -3
